Scientific Presentations
L-CsA-i and the eFlow® for L-CsA-i are investigational and their safety and efficacy have not been established for the uses described here.
Use Of Functional Respiratory Imaging (FRI) To Explore Drug Delivery And Lung Deposition Of Inhaled Liposomal Cyclosporine A (L-CsA-i) In Patients After Lung Transplantation
ATS 2020
Pediatric Patients with Bronchiolitis Obliterans Syndrome (BOS): Dosing and Breath Simulation
Experiments of Liposomal Cyclosporin A for Inhalation (L-CsA-i)
ATS 2020
Prevalence of Bronchiolitis Obliterans Syndrome Following Allogeneic
Haematopoietic Stem Cell Transplant in the United States, Europe, and Japan
EBMT 2020
The Economic Burden of Bronchiolitis Obliterans Syndrome (BOS) in Lung Transplantation Patients with Medicare Coverage
ISPOR Orlando 2020
The Economic Burden of Bronchiolitis Obliterans Syndrome (BOS) in Allogeneic Hematopoietic Stem Cell Transplant (AlloHSCT) Patients with Medicare Coverage
ISPOR Orlando 2020
Real World Trends in Monitoring Lung Transplant Recipients for Lung Allograft Dysfunction
ISPOR Orlando 2020
Economic Burden of Bronchiolitis Obliterans Syndrome (BOS) Following Allogeneic Hematopoietic Stem Cell Transplant (alloHSCT) in Patients with Commercial Insurance in the United States
ASH Orlando 2019
The clinical, humanistic and economic burden of bronchiolitis obliterans syndrome in Europe
ISPOR Europe Copenhagen 2019
A randomised single-centre trial of inhaled liposomal cyclosporine for bronchiolitis obliterans syndrome post-lung transplantation
Iacono et al. ERJ Open Research 2019
Liposomal Cyclosporine A for Inhalation (L-CsA-i): Innovation in the Treatment of Bronchiolitis Obliterans Syndrome (BOS)
NORD Washington 2019
ISHLT Registry Data and Country Registries: Comparison of Reported European/Israeli Lung
Transplant Activities in 2016
ERS Madrid 2019
L-CsA-i, a Liposomal Formulation of Cyclosporine, Demonstrates Therapeutic Potential for Bronchiolitis Obliterans Syndrome (BOS)
ATS Dallas 2019
Liposomal Cyclosporine A for Inhalation (L-CsA-i) to Treat Bronchiolitis Obliterans Syndrome: Novel Formulation and Drug-Specific Delivery System Improve Tolerability
ISHLT Orlando 2019
Liposomal Cyclosporine A for Inhalation (L-CsA-i) to Treat Bronchiolitis Obliterans Syndrome (BOS): Novel Formulation With Therapeutic Potential for Patients With BOS Following allo-HSCT
EBMT Frankfurt 2019